Crude cumulative incidence
Fig. 3 · Panel A
Panel A 是同一 Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Giacomo Biganzoli, Edoardo Isnaldi, François Richard, Giuseppe Marano, Patrizia Boracchi, Marion Maetens, Giuseppe Floris, Patrick Neven, Guy Jerusalem, Elisabetta Munzone, Erika Hitre, Andrea Gombos, Alastair Thompson, Stefan Aebi, Roswitha Kammler, Patrizia Dell'Orto, Giuseppe Viale, Meredith M Regan, Marco Colleoni, Elia Biganzoli, Christine Desmedt
Eur J Cancer 222 115438
BACKGROUND: Obesity is associated with a greater risk of developing distant recurrences in patients with estrogen receptor-positive (ER+) breast cancer. This association is however poorly investigated in patients treated with extended endocrine treatment (ET). We therefore evaluated the prognostic role of BMI in the SOLE trial, where postmenopausal patients, after having completed 4-6 years of adjuvant ET, were treated with 5 additional years of continuous or intermittent letrozole. PATIENTS & METHODS: We considered the 3606 patients with ER+ /HER2- lymph node-positive BC with available BMI from the SOLE trial (NCT00553410). Distant-recurrence free interval (DRFI) was the main endpoint, and breast cancer-free interval (BCFI), disease-free survival (DFS) and overall survival (OS) secondary endpoints. Adjusted risk ratios (RR) for distant metastases were estimated with crude cumulative incidence models. RESULTS: 38.6 % of the patients were underweight or normal weight, 36.5 % overweight and 24.9 % obese. BMI was associated with age, tumor size, number of positive lymph nodes, menopausal status and type of prior ET. In the adjusted analyses, the prognostic value of BMI was dependent on prior ET and extended ET arm (second-order interaction p-value<0.001 for DRFI, BCFI and DFS, but not for OS). For instance, in patients treated with both a selective estrogen receptor modulator and an aromatase inhibitor in the first five years, obesity, as compared to normal-weight, was associated with better (RRDRFI=0.61, 95 %CI: 0.42-0.90) and worse (RRDRFI=2.31, 95 %CI: 1.41-3.78) outcomes in the adjusted models, in patients treated with continuous and intermittent letrozole in the extended ET, respectively. CONCLUSION: We observed that the prognostic relation of BMI changes according to the type of adjuvant ET and mode of administration of extended AI. This warrants further investigation.
1 个 Figure · 6 个 KM 面板
Fig. 3 Prognostic association of categorical BMI with BCFI. ( A) Unadjusted non-parametrical estimates of CCI of BC recurrences conditioned on prior endocrine treatment, treatment arm and BMI category. (B) Forest plot of the estimated risk ratios of BC recurrences between patients with normal weight and overweight (blue) and between patients with normal weight and obesity (purple) adjusted for tumor size, grade, histology, number of positive lymph nodes, and age. Patients with normal weight are the reference category. (C) Estimated risk ratios for the other covariates in the multivariable model: tumor grade, tumor size, histology, and number of positive lymph nodes. (D) Plot of the non-linear effect of age, modelled with a restricted cubic spline. The risk ratios (solid line) are computed with respect to a subject of 53 years of age as the reference. Dashed lines represent the 95 % CIs. Abbreviations: BC: breast cancer; BCFI: breast cancer free interval; BMI: body mass index; CCI: crude cumulative incidence; CIs: confidence intervals.
Fig. 3 · Panel A
Panel A 是同一 Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 3 · Panel A_2
Panel A_2 是同一 Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 3 · Panel A_3
Panel A_3 是同一 Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 3 · Panel A_4
Panel A_4 是同一 Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 3 · Panel A_5
Panel A_5 是同一 Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 3 · Panel A_6
Panel A_6 是同一 Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
这些图片未产生 KM 曲线结果,不在主页面重复展示。